Randomized, placebo-controlled trials of antidepressants for acute major depression: Thirty-year meta-analytic review

Neuropsychopharmacology

Volumn 37, Issue 4, 2012, Pages 851-864

  Undurraga, Juan ^a,b   Baldessarini, Ross J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

antidepressants; controlled trials; depression; evidence based medicine; meta analysis; secular changes

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; IMIPRAMINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SELEGILINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; VENLAFAXINE;

DRUG EFFICACY; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE;

ACUTE DISEASE; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; EVIDENCE-BASED MEDICINE; HUMANS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84857039429     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.306     Document Type: Review

References (135)

1. Amsterdam JD (2003). Double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 64: 208-214. (Pubitemid 36268325)
2. Anderson B (1990). Methodological Errors in Medical Research: Incomplete Catalog. Blackwell: New York.
3. Anderson IM (2001). Meta-Analytical studies on new antidepressants. Br Med Bull 57: 161-178. (Pubitemid 32612677)
4. Andreoli V, Caillard V, Deo RS, Rybakowski JK, Versiani M (2002). Reboxetine, new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 22: 393-399. (Pubitemid 34810329)
5. Baldessarini RJ (2005). Drug therapy of depression and anxiety disorders. Chapter 17. In: Brunton LL, Lazo JS, Parker KL (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill: New York, pp 429-459.
6. Baldessarini RJ (2012). Chemotherapy in Psychiatry, 3rd edn. New York: Springer-Verlag (in press).
7. Baldessarini RJ, Tondo L, Ghiani C, Lepri B (2010). Discontinuation rate vs recurrence risk following long-term antidepressant treatment in major depressive disorder patients. Am J Psychiatry 167: 934-941.
8. Bakish D, Bradwejn J, Nair N, McClure J, Remick R, Bulger L (1992). Comparison of moclobemide, amitriptyline and placebo in depression: Canadian multicenter study. Psychopharmacology 106(Suppl): S98-S101.
9. Ban TA, Aguglia E, Batista R, Castillo A, Lipcsey A, Macher JP et al (1998). Clinical efficacy of reboxetine: Comparative study with desipramine, with methodological considerations. Hum Psychopharmacol 13(Suppl): S29-S39. (Pubitemid 28109324)
10. Bjerkenstedt L, Edman GV, Alken RG, Mannel M (2005). Hypericum extract LI-160 and fluoxetine in mild to moderate depression: Randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci 255: 40-47. (Pubitemid 40558104)
11. Bland JM, Altman DG (1994). Regression towards the mean. BMJ 308: 1499-1500.
12. Bodkin A, Amsterdam JD (2002). Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 159: 1869-1875. (Pubitemid 35283252)
13. Boyer P, Montgomery S, Lepola U, Germain JM, Brisard C, Ganguly R et al (2008). Efficacy, safety, and tolerability of fixeddose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 23: 243-253.
14. Brannan SK, Mallinckrodt CH, Brown EB, Wohlreich MM, Watkin JG, Schatzberg AF (2005). Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 39: 43-53. (Pubitemid 39422285)
15. Bremner JD (1995). Double-blind comparison of Org-3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 56: 519-525.
16. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA (2009). Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 166: 42-49.
17. Burke WJ, Gergel I, Bose A (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63: 331-336. (Pubitemid 34456361)
18. Carman JS, Ahdieh H, Wyatt-Knowles E, Warga E, Panagides J (1991). Controlled study of mianserin in moderately to severely depressed outpatients. Psychopharmacol Bull 27: 135-139.
19. Cassano GB, Heinze G, Lôo H, Mendlewicz J, Sousa MP (1996). Double-blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes. Eur Psychiatry 11: 254-259. (Pubitemid 26331473)
20. Cipriani A, Geddes JR, Furukawa TA, Barbui C (2007). Metareview on short-term effectiveness and safety of antidepressants for depression: Evidence-based approach to inform clinical practice. Can J Psychiatry 52: 553-562. (Pubitemid 47523282)
21. Claghorn J, Gershon S, Goldstein BJ, Behrnetz S, Bush DF, Huitfeldt B (1983). Double-blind evaluation of zimelidine in comparison to placebo and amitriptyline in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 7: 367-382. (Pubitemid 13077550)
22. Claghorn JL, Earl CQ, Walczak DD, Stoner KA, Wong LF, Kanter D et al. (1996). Fluvoxamine maleate in the treatment of depression: Single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. J Clin Psychopharmacol 16: 113-120. (Pubitemid 26142899)
23. Claghorn JL, Kiev A, Rickels K, Smith WT, Dunbar GC (1992). Paroxetine vs placebo: Double-blind comparison in depressed patients. J Clin Psychiatry 53: 434-438. (Pubitemid 23018086)
24. Claghorn JL, Lesem MD (1995). Double-blind placebo-controlled study of Org-3770 in depressed outpatients. J Affect Disord 34: 165-171.
25. Clayton AH, Croft HA, Horrigan JP, Wightman DS, Krishen A, Richard NE et al (2006). Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in two randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 67: 736-746. (Pubitemid 43946180)
26. Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O'Brien K, Ieni JR (1996). Responders to antidepressant drug treatment: Study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 57(Suppl 2): 15-18. (Pubitemid 26143974)
27. Cohn JB, Wilcox C (1985). Comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 46: 26-31. (Pubitemid 15139186)
28. Cohn JB, Wilcox CS (1992). Paroxetine in major depression: Double-blind trial with imipramine and placebo. J Clin Psychiatry 53(Suppl): 52-56.
29. Coleman CC, Cunningham LA, Foster VJ, Batey SR, Donahue RM, Houser TL et al (1999). Sexual dysfunction associated with the treatment of depression: Placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 11: 205-215.
30. Coleman CC, King BR, Bolden-Watson C, Book MJ, Segraves RT, Richard N et al (2001). Placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 23: 1040-1058. (Pubitemid 32709626)
31. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL (2000). Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11: 58-65. (Pubitemid 30228411)
32. Croft H, Settle Jr. E, Houser T, Batey SR, Donahue RM, Ascher JA (1999). Placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 21: 643-658. (Pubitemid 29252088)
33. Cunningham LA (1997). Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Ann Clin Psychiatry 9: 157-164. (Pubitemid 27470387)
34. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI et al (1994). Comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 14: 99-106. (Pubitemid 24120707)
35. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Astrom M, Brecher M (2009). Extended release quetiapine fumarate monotherapy in major depressive disorder: Placebo-And duloxetine-controlled study. J Clin Psychiatry 70: 526-539.
36. Davidson JR (2002). Effect of Hypericum perforatum (St John's wort) in major depressive disorder: Randomized controlled trial. JAMA 287: 1807-1814. (Pubitemid 34303625)
37. DeMartinis NA, Yeung PP, Entsuah R, Manley AL (2007). Doubleblind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 68: 677-688. (Pubitemid 46841850)
38. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA (2002a). Duloxetine, 60 mg once daily, for major depressive disorder: A randomized double-blind placebo-controlled trial. J Clin Psychiatry 63: 308-315. (Pubitemid 34456358)
39. Detke MJ, Lu Y, Goldstein DJ, McNamara RK, Demitrack MA (2002b). Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 36: 383-390. (Pubitemid 35254112)
40. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I (2004). Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo-And paroxetinecontrolled trial. Eur Neuropsychopharmacol 14: 457-470. (Pubitemid 39626894)
41. Doogan DP, Langdon CJ (1994). Double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 9: 95-100. (Pubitemid 24160564)
42. Fabre LF (1992). Six-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. J Clin Psychiatry 53(Suppl): 40-43.
43. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM et al (1995). Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo. Biol Psychiatry 38: 592-602.
44. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J et al (2005). Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 25: 441-447. (Pubitemid 41368366)
45. Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL (1998). Double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 10: 145-150. (Pubitemid 29078266)
46. Feiger AD (1996). Double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. Psychopharmacol Bull 32: 659-665. (Pubitemid 26428270)
47. Feiger AD, Rickels K, Rynn MA, Zimbroff DS, Robinson DS (2006). Selegiline transdermal system for the treatment of major depressive disorder: An 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 67: 1354-1361. (Pubitemid 44583382)
48. Feiger AD, Tourian KA, Rosas GR, Padmanabhan SK (2009). Placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. CNS Spectrums 14: 41-50.
49. Feighner JP (1992). Double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients. Int Clin Psychopharmacol 6(Suppl 4): 31-35.
50. Feighner JP, Aden GC, Fabre LF, Rickels K, Smith WT (1983). Comparison of alprazolam, imipramine, and placebo in the treatment of depression. JAMA 249: 3057-3064. (Pubitemid 13098488)
51. Feighner JP, Boyer WF, Merideth CH, Hendrickson GG (1989a). Double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. Int Clin Psychopharmacol 4: 127-134.
52. Feighner JP, Boyer WF, Meredith CH, Hendrickson GG (1989b). Placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 4: 239-244.
53. Feighner JP, Cohn JB, Fabre Jr. LF, Fieve RR, Mendels J, Shrivastava RK et al (1993). Study comparing paroxetine, placebo, and imipramine in depressed patients. J Affect Disord 28: 71-79. (Pubitemid 23178094)
54. Feighner JP, Overo K (1999). Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry 60: 824-830.
55. Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S et al (1994). Double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 55: 234-241. (Pubitemid 24235835)
56. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVaugh-Geiss A, Krebs EE et al (2008). Comparative benefits and harms of secondgeneration antidepressants. Ann Intern Med 149: 734-750.
57. Gastpar M, Singer A, Zeller K (2006). Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: Double-blind, randomized, multicentre, placebo-controlled study. Pharmacopsychiatry 39: 66-75.
58. Gelenberg AJ, Wojcik JD, Falk WE, Baldessarini RJ, Zeisel SH, Schoenfeld D et al. (1990). Tyrosine for depression: Double-blind trial. J Affect Disord 19: 125-132.
59. Ghaemi SN (2008). Why antidepressants are not antidepressants. Bipolar Disord 10: 957-968.
60. Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dube EM (2002). Efficacy and tolerability of controlled-release and immediaterelease paroxetine in the treatment of depression. J Clin Psychiatry 63: 577-584. (Pubitemid 34787322)
61. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA (2004). Duloxetine in the treatment of depression: Doubleblind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 24: 389-399. (Pubitemid 38944137)
62. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA (2002). Duloxetine in the treatment of major depressive disorder: Double-blind clinical trial. J Clin Psychiatry 63: 225-231. (Pubitemid 34407082)
63. Guelfi JD, White C, Hackett D, Guichoux JY, Magni G (1995). Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 56: 450-458.
64. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. US Department HEW publication (ADM) 76-338: Rockville, MD. National Institute of Mental Health, pp 218-222.
65. Hamilton M (1960). Rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
66. Healy D (1997). The Antidepressant Era. Harvard University: Cambridge, MA.
67. Hewett K, Gee MD, Krishen A, Wunderlich HP, Le Clus A, Evoniuk G et al (2010). Double-blind, placebo-controlled comparison of antidepressant efficacy and tolerability of bupropion-XR and venlafaxine-XR. J Psychopharmacol 24: 1209-1216.
68. Hollyman JA, Freeling P, Paykel ES, Bhat A, Sedgwick P (1988). Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice. J R Coll Gen Pract 38: 393-397.
69. Ioannidis JP (2008). Effectiveness of antidepressants: An evidence myth constructed from a thousand randomized trials? Philos Ethics Humanit Med 3: 14-22.
70. Itil TM, Shrivastava RK, Mukherjee S, Coleman BS, Michael ST (1983). Double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. Br J Clin Pharmacol 15(Suppl 3): S433S-S4338.
71. Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD et al (2006). Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: Findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67: 865-873. (Pubitemid 44049084)
72. Khan A, Fabre LF, Rudolph R (1991). Venlafaxine in depressed outpatients. Psychopharmacol Bull 27: 141-144.
73. Khan A, Upton GV, Rudolph RL, Entsuah R, Leventer SM (1998). Use of venlafaxine in the treatment of major depression and major depression associated with anxiety: Dose-response study. J Clin Psychopharmacol 18: 19-25. (Pubitemid 28045630)
74. Khan M (1995). Randomized, double-blind, placebo-controlled, 5-weeks study of Org-3770 (mirtazapine) in major depression. Hum Psychopharmacol 10(Suppl): S119-S124.
75. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2011). Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applicatons. J Clin Psychiatry 72: 464-472.
76. Kiev A (1992). Double-blind, placebo-controlled study of paroxetine in depressed outpatients. J Clin Psychiatry 53(Suppl): S27-S29.
77. Kirsch I, Deacon B, Huedo-Medina TB, Moore TJ, Johnson BT (2008). Initial severity and antidepressant benefits: Meta-Analysis of data submitted to the Food and Drug Administration. PLoS Med 5: E45-e53.
78. Laakman G, Faltermaier-Temizel M, Bossert-Zaudig S, Baghai T, Lorkowski G (1995). Treatment of depressive outpatients with lorazepam, alprazolam, amitriptyline and placebo. Psychopharmacology 120: 109-115.
79. Larsen JK, Holm P, Hyer E, Mejlhede A, Mikkelsen PL, Olesen A et al (1989). Moclobemide and clomipramine in reactive depression: Placebo-controlled randomized clinical trial. Acta Psychiatr Scand 79: 530-536. (Pubitemid 19168597)
80. Lecrubier Y, Bourin M, Moon CA, Schifano F, Blanchard C, Danjou P et al (1997). Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 95: 485-493. (Pubitemid 27272198)
81. Lepola UM, Loft H, Reines EH (2003). Escitalopram (10-20 mg/ day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18: 211-217. (Pubitemid 36871872)
82. Lieberman DZ, Montgomery SA, Tourian KA, Brisard C, Rosas G, Padmanabhan K et al (2008). A pooled analysis of two placebocontrolled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 23: 188-197.
83. Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA (2008). Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin 24: 1877-1890.
84. Liebowitz MR, Yeung PP, Entsuah R (2007). Randomized, doubleblind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 68: 1663-1672. (Pubitemid 350247495)
85. Lineberry CG, Johnston JA, Raymond RN, Samara B, Feighner JP, Harto NE et al (1990). Fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. J Clin Psychiatry 51: 194-199. (Pubitemid 20159096)
86. Lydiard RB, Stahl SM, Hertzman M, Harrison WM (1997). Doubleblind, placebo-controlled study comparing the effects of sertraline vs amitriptyline in the treatment of major depression. J Clin Psychiatry 58: 484-491. (Pubitemid 27527444)
87. Masi G, Liboni F, Brovedani P (2010). Pharmacotherapy of major depressive disorder in adolescents. Expert Opin Pharmacother 11: 375-386.
88. Massana J (1998). Reboxetine vs fluoxetine: Overview of efficacy and tolerability. J Clin Psychiatry 59(Suppl 14): 8-10. (Pubitemid 28462382)
89. Mendels J, Kiev A, Fabre LF (1999). Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia. Depress Anxiety 9: 54-60. (Pubitemid 29177714)
90. Mendels J, Schless AP (1986). Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. J Clin Psychiatry 47: 357-361. (Pubitemid 16057605)
91. Miller SM, Naylor GJ, Murtagh M, Winslow G (1989). Double-blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic. Acta Psychiatr Scand Suppl 350: 143-144. (Pubitemid 19236664)
92. Montgomery SA, Åsberg M (1979). New depression scale designed to be sensitive to change. Br J Psychiatry 134: 382-389. (Pubitemid 9136500)
93. Moreno RA, Teng CT, Almeida KM, Tavares JH (2006). Hypericum perforatum vs fluoxetine in the treatment of mild to moderate depression: Randomized double-blind trial in a Brazilian sample. Rev Bras Psiquiatr 28: 29-32.
94. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D (1995). Randomized controlled trial comparing problem-solving treatment with amitriptyline and placebo for major depression in primary care. BMJ 310: 441-445.
95. Nemeroff CB, Thase ME (2007). Double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 41: 351-359. (Pubitemid 44854984)
96. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD et al (2007). Duloxetine vs escitalopram and placebo in the treatment of patients with major depressive disorder: Onset of antidepressant action, non-inferiority study. Curr Med Res Opin 23: 401-416. (Pubitemid 46333388)
97. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? Meta-Analysis of studies of newer agents. Biol Psychiatry 62: 1217-1227. (Pubitemid 350060895)
98. Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ (2006). Duloxetine in the treatment of major depressive disorder: Placeboand paroxetine-controlled trial. Eur Psychiatry 21: 367-378.
99. Philipp M, Kohnen R, Hiller KO (1999). Hypericum extract vs imipramine or placebo in patients with moderate depression: Randomized multicenter study of treatment for eight weeks. BMJ 319: 1534-1538.
100. Pigott HE, Leventhal AM, Alter GS, Boren JJ (2010). Efficacy and effectiveness of antidepressants: Current status of research. Psychother Psychosom 79: 267-279.
101. Pitts WM, Fann WE, Halaris AE, Dressler DM, Sajadi C, Snyder S et al (1983). Bupropion in depression: Tri-center placebocontrolled study. J Clin Psychiatry 44(Part 2): 95-100. (Pubitemid 13088845)
102. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Wager SG, Nunes E et al (1989). Phenelzine and imipramine in mood reactive depressives: Further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 46: 787-793. (Pubitemid 19233227)
103. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, LaPierre YD et al (1990). Antidepressant efficacy of sertraline: Doubleblind, placebo-And amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 51(Suppl B): S18-S27.
104. Reimherr FW, Cunningham LA, Batey SR, Johnston JA, Ascher JA (1998). Multicenter evaluation of the efficacy and safety of 150 and 300 mg/day sustained-release bupropion tablets vs placebo in depressed outpatients. Clin Ther 20: 505-516. (Pubitemid 28343503)
105. Rickels K, Amsterdam J, Clary C, Fox I, Schweizer E, Weise C (1992). Efficacy and safety of paroxetine compared with placebo in outpatients with major depression. J Clin Psychiatry 53(Suppl): S30-S32.
106. Rickels K, Chung HR, Csanalosi IB, Hurowitz AM, London J, Wiseman K et al (1987). Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry 44: 862-866. (Pubitemid 17155443)
107. Rickels K, Feighner JP, Smith WT (1985). Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression. Arch Gen Psychiatry 42: 134-141. (Pubitemid 15246355)
108. Rickels K, Schweizer E, Clary C, Fox I, Weise C (1994). Nefazodone and imipramine in major depression: A placebo-controlled trial. Br J Psychiatry 164: 802-805. (Pubitemid 24186900)
109. Roth D, Mattes J, Sheehan KH, Sheehan DV (1990). Double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. Prog Neuropsychopharmacol Biol Psychiatry 14: 929-939. (Pubitemid 20373163)
110. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R, Derivan AT (1998). Randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 59: 116-122. (Pubitemid 28150857)
111. Rudolph RL, Feiger AD (1999). Double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 56: 171-181. (Pubitemid 30058219)
112. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996). Evidence based medicine: What it is and what it isn't. BMJ 12: 71-72.
113. Schweizer E, Feighner J, Mandos LA, Rickels K (1994). Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 55: 104-108. (Pubitemid 24116436)
114. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA (2007). Randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 22: 338-347. (Pubitemid 47530838)
115. Sheehan DV, Nemeroff CB, Thase ME, Entsuah R (2009). Placebocontrolled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. Int Clin Psychopharmacol 24: 61-86.
116. Silverstone PH (1994). Multicenter comparative trial of moclobemide, imipramine and placebo in major depressive disorder. Int Clin Psychopharmacol 9: 109-113.
117. Silverstone PH, Ravindran A (1999). Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 60: 22-28. (Pubitemid 29069881)
118. Smith WT, Glaudin V, Panagides J, Gilvary E (1990). Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 26: 191-196. (Pubitemid 20291874)
119. Stahl SM (2000). Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. Biol Psychiatry 48: 894-901.
120. Thase ME (1997). Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 58: 393-398. (Pubitemid 27438691)
121. Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D (2009). Desvenlafaxine 50 and 100 mg/day in the treatment of major depressive disorder: An 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther 31: 1405-1423.
122. Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD (2004). Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J Clin Psychiatry 65: 1356-1364.
123. Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ (2008). Efficacy of antidepressants in juvenile depression: Meta-Analysis. Br J Psychiatry 193: 10-17. (Pubitemid 351946803)
124. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008). Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252-260.
125. Vartiainen H, Leinonen E (1994). Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur Neuropsychopharmacol 4: 145-150. (Pubitemid 24199864)
126. Vázquez G, Baldessarini RJ, Yildiz A, Tamayo J, Tondo L, Salvatore P (2011). Multi-site international collaborative clinical trials in mania: Commentary. Int J Neuropsychopharmacol 14: 1013-1016.
127. Wade A, Michael-Lemming MO, Bang-Hedegaard K (2002). Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17: 95-102. (Pubitemid 34442189)
128. Walsh BT, Seidman SN, Sysko R, Gould M (2002). Placebo response in studies of major depression: Variable, substantial, and growing. JAMA 287: 1840-1847. (Pubitemid 34303629)
129. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M (1988). Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 24: 183-188.
130. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL (1987). Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 23: 164-168. (Pubitemid 17111687)
131. White K, Razani J, Cadow B, Gelfand R, Palmer R, Simpson G et al (1984). Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: A controlled trial. Psychopharmacology 82: 258-262. (Pubitemid 14184555)
132. Wilcox CS, Cohn JB, Katz BB, Mijares CP, Guarino JJ, Panagides J et al (1994). Double-blind, placebo-controlled study comparing mianserin and amitriptyline in moderately depressed outpatients. Int Clin Psychopharmacol 9: 271-279. (Pubitemid 24374888)
133. Wooley SB, Cardoni AA, Goethe JW (2009). Last-observation carried forward imputation method in clnical efficacy trials: Review of 352 antidepressant studies. Pharmacotherapy 29: 1408-1416.
134. Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011a). Efficacy of antimanic treatments: Meta-Analysis of randomized, controlled trials. Neuropsychopharmacology 36: 375-389.
135. Yildiz A, Vieta E, Tohen M, Baldessarini RJ (2011b). Placebo effects in treatment trials for acute mania. Int J Neuropsychopharmacol 14: 863-875.